OAM
ESPR

Oxford Asset Management’s Esperion Therapeutics ESPR Stock Holding History

Oxford Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27,330
Closed -$74.9K – 456
2026
Q1 		$74.9K Buy
+27,330
New +$86.5K 0.03% 441
2025
Q4 		– Sell
-46,270
Closed -$123K – 577
2025
Q3 		$123K Buy
+46,270
New +$89.5K 0.04% 402
2024
Q3 		– Sell
-42,161
Closed -$93.6K – 348
2024
Q2 		$93.6K Buy
+42,161
New +$99.2K 0.09% 242
2020
Q1 		– Sell
-17,182
Closed -$1.02M – 569
2019
Q4 		$1.02M Sell
17,182
-31,170
-64% -$1.4M 0.03% 849
2019
Q3 		$1.77M Buy
48,352
+737
+2% +$29.2K 0.04% 620
2019
Q2 		$2.21M Buy
+47,615
New +$2.24M 0.05% 599
2019
Q1 		– Sell
-23,472
Closed -$1.08M – 1743
2018
Q4 		$1.08M Buy
23,472
+12,676
+117% +$611K 0.03% 831
2018
Q3 		$485K Buy
+10,796
New +$496K 0.01% 1321
2018
Q2 		– Sell
-11,046
Closed -$799K – 1762
2018
Q1 		$799K Buy
+11,046
New +$811K 0.02% 1044
2017
Q4 		– Sell
-14,309
Closed -$715K – 1673
2017
Q3 		$715K Buy
+14,309
New +$690K 0.01% 1083
2017
Q2 		– Sell
-25,211
Closed -$890K – 1530
2017
Q1 		$890K Sell
25,211
-4,440
-15% -$102K 0.02% 854
2016
Q4 		$371K Sell
29,651
-36,290
-55% -$432K 0.01% 633
2016
Q3 		$913K Sell
65,941
-171,002
-72% -$1.94M 0.03% 532
2016
Q2 		$2.34M Sell
236,943
-43,399
-15% -$719K 0.08% 338
2016
Q1 		$4.74M Buy
280,342
+125,265
+81% +$2.02M 0.14% 172
2015
Q4 		$3.53M Buy
+155,077
New +$3.91M 0.08% 269

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Oxford Asset Management's ESPR Position: Q2 2026 in Review

Oxford Asset Management sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 27,330 shares — an estimated $74.9K sold.

Oxford Asset Management first reported a position in ESPR in Q4 2015 and held it in 16 quarters. The position peaked at $4.74M in Q1 2016. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Oxford Asset Management reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Oxford Asset Management sold 27,330 Esperion Therapeutics shares in Q2 2026, an estimated $74.9K.
  • Oxford Asset Management first reported a position in Esperion Therapeutics in Q4 2015 and held it in 16 quarters.
  • Oxford Asset Management's Esperion Therapeutics position peaked at $4.74M in Q1 2016.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Oxford Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.